In brief
The FDA is undergoing a leadership overhaul with the removal of Dr. Tracy Beth Hoeg, previously at the helm of its drug program, following Commissioner Marty Makary's resignation. Hoeg's leadership had been marked by controversy, including scrutiny over COVID-19 vaccine safety investigations and antidepressant warnings. Dr. Mike Davis has been named her successor amid ongoing tensions within the agency and criticisms from various stakeholders.
WASHINGTON (AP) — In a notable shake-up within the Food and Drug Administration (FDA), Dr. Tracy Beth Hoeg has been removed from her position leading the agency’s drug program. Hoeg's departure comes shortly after the resignation of FDA Commissioner Marty Makary, further escalating concerns over the agency's direction and leadership stability. Dr. Mike Davis, previously the deputy director, will succeed Hoeg as the acting director, according to an internal email shared with staff. Hoeg herself confirmed her firing in a social media post, stating she learned a great deal during her tenure and harbors no regrets.This leadership change marks another chapter in a turbulent period for the FDA, which has faced scrutiny over its regulation of vaccines and other therapies amid rising criticism from pharmaceutical stakeholders and public health groups. Makary’s exit followed weeks of discontent from political allies of former President Trump, including anti-abortion activists and those aligned with the vaping industry, who felt the agency's agenda was misaligned with their interests.Hoeg, appointed as acting drug center director last December, had previously been involved in investigating the safety of antidepressants, COVID-19 vaccines, and RSV treatments for children. Her rapid rise was attributed to Makary, who promoted her from a special assistant position to oversee a key division affecting most U.S. prescription and over-the-counter medications.Before her governmental role, Hoeg gained visibility as a public figure criticizing masking policies and vaccine mandates during the pandemic. Her posts and collaborations with other controversial figures, including Makary and Dr. Vinay Prasad, raised eyebrows over her suitability for her role at the FDA, an agency typically led by seasoned scientists.Despite her short tenure, Hoeg's investigations drew considerable attention, including a controversial analysis associating COVID-19 vaccines with child fatalities—findings that the agency has yet to formalize. She also drew criticism for her involvement in reviewing proposals to add cautionary labels to antidepressants concerning alleged pregnancy risks.The FDA continues to navigate an uncertain landscape, with new leadership stepping in to address pressing public health challenges and regulatory demands amid ongoing scrutiny from all sides.
